Kimoto Naoki, Miyashita Yohei, Yata Yutaka, Aketa Takeshi, Yabumoto Masami, Sakata Yasushi, Washio Takashi, Takashima Seiji, Kitakaze Masafumi
Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Non Profit Organization Think of Medicine in Science, 3-7-11, Minamisumiyoshi, Sumiyoshi-ku, Osaka, Japan.
Heart Vessels. 2025 Apr;40(4):350-360. doi: 10.1007/s00380-024-02474-7. Epub 2024 Oct 9.
Since many people die of either cancers or cardiovascular diseases worldwide, it is important to find the clinical pitfall that provokes cardiovascular diseases and cancer overall. Since metabolic syndrome (MetS) is largely linked to cardiovascular diseases, we have come to consider that MetS, even in its early state, may prime the occurrence of cancers overall. Indeed, the importance of MetS in causing pancreatic cancer has been proved using our large medical database. We analyzed Japanese healthcare and clinical data in 2005, who were followed up until 2020 and we examined the incidence of major cancers. At the enrollment, we examined the presence or absence of MetS judged by either Japanese criteria or NCEP/ATPIII. Of 2.7 million subjects without missing data, 102,930; 200,231; 237,420; 63,435; 76,172; and 2,422 subjects suffered lung, stomach, colon, liver and prostate cancer, respectively, and myelogenous leukemia during follow-up. MetS, defined by Japanese criteria, increased (p < 0.005 each) the incidence of cancer with a hazard ratio (HR) of 1.03-1.47 for lung, stomach, colon, liver, prostate cancers, and myelogenous leukemia. According to Japanese criteria, cancer incidence in the pre-stage MetS group was comparable to the MetS group. The results were almost identical when we defined MetS using NCEP ATP III. Taken together, we conclude that MetS is linked to majority of cancers.
由于全球有许多人死于癌症或心血管疾病，因此找出引发心血管疾病和癌症的临床隐患非常重要。由于代谢综合征（MetS）与心血管疾病密切相关，我们开始认为，即使是处于早期阶段的MetS，也可能引发整体癌症的发生。事实上，利用我们庞大的医学数据库已证明了MetS在引发胰腺癌方面的重要性。我们分析了2005年日本的医疗保健和临床数据，对这些数据进行追踪直至2020年，并研究了主要癌症的发病率。在入组时，我们根据日本标准或美国国家胆固醇教育计划成人治疗组第三次报告（NCEP/ATPIII）来判断是否存在MetS。在270万无缺失数据的受试者中，分别有102,930、200,231、237,420、63,435、76,172和2,422名受试者在随访期间患肺癌、胃癌、结肠癌、肝癌、前列腺癌和骨髓性白血病。按照日本标准定义的MetS使肺癌、胃癌、结肠癌、肝癌、前列腺癌和骨髓性白血病的癌症发病率增加（每项p < 0.005），风险比（HR）为1.03至1.47。根据日本标准，MetS前期组的癌症发病率与MetS组相当。当我们使用NCEP ATP III定义MetS时，结果几乎相同。综上所述，我们得出结论，MetS与大多数癌症有关。
